Skip to main content
TipRanks
Go Ultimate75% OFF

Mediwound (MDWD) AI Stock Analysis

467 Followers
MDWD

Mediwound

(NASDAQ:MDWD)

Select Model
Rating:46Neutral
Price Target:$12.50â–¼(-8.63% Downside)
Action:reiterated
Date:11/14/26

The score is primarily weighed down by weak financial performance (contracting revenue, large losses, and significant ongoing cash burn). Technicals are mixed with the stock trading below key moving averages, while the earnings call provided meaningful development and demand positives that are tempered by funding uncertainty and supply constraints. Valuation offers limited support due to negative earnings and no dividend yield provided.

Positive Factors
Growing NexoBrid AdoptionBroadening use across burn centers, together with a high proportion of repeat ordering, indicates meaningful product adoption and customer retention. This commercial traction can support recurring demand and strengthen NexoBrid’s position in specialized burn-care protocols as distribution expands.
Negative Factors
Contracting Revenue and Deep LossesThe sharp revenue decline leaves the current cost base poorly supported, while deeply negative net margins show that commercial activity has not yet translated into sustainable profitability. Continued operating deleverage could constrain investment capacity and increase reliance on external funding.

Mediwound (MDWD) vs. SPDR S&P 500 ETF (SPY)

-30%-20%-10%0%10%20%MDWD-18.86%SPY+11.73%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$176.61M
Dividend Yield
―
Average Volume (3M)
120.90K
Price to Earnings (P/E)
-7.5
Beta (1Y)
0.85
Revenue Growth
-52.19%
EPS Growth
3.91%
Country
US
Employees
121
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

Mediwound Business Overview & Revenue Model

Company Description

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in the United States, Germany, Italy, Spain, and internationally. The compan...

How the Company Makes Money

MediWound generates revenue primarily through (1) product sales of its burn debridement therapy NexoBrid in markets where it is commercialized and reimbursed, and (2) collaboration, license, and service-related income tied to partnerships for develop...

Mediwound Earnings Call Summary

Earnings Call Date:Nov 12, 2026(Q3-2026)|% Change Since:-1.01%|Next Earnings Date:Mar 18, 2027
Earnings Call SentimentNeutral

The call had meaningful operational and development positives, including strong NexoBrid demand, positive VALUE trial safety reviews, progress toward enrollment and additional funding for NexoBrid programs. However, these were offset by lower revenue, widening operating and adjusted EBITDA losses, substantial cash burn, supply-constrained product sales, and uncertainty around U.S. government funding that affects the 2026 outlook and a significant portion of 2027 guidance. Overall, the positive and negative factors were relatively balanced.

Positive Updates

VALUE Trial Enrollment Remains on Track
MediWound said enrollment in the global Phase III VALUE trial for venous leg ulcers remains on track for completion by the end of the first quarter of 2027. The current target is 216 patients across approximately 40 sites, and management said approximately 95% of sites are currently open.

Negative Updates

Third-Quarter Revenue Declined
Third-quarter revenue was $3.6 million, down from $5.4 million in the third quarter of 2025. The decrease was primarily attributable to lower revenue from development services related to the U.S. government.

Company Guidance

Management said the VALUE trial’s current enrollment target is 216 patients across approximately 40 sites, with enrollment expected to be completed by the end of the first quarter of 2027; the interim sample size reassessment is planned after treatment of 140-ish patients to confirm 85% statistical power, followed by around 3 months of treatment and another couple of weeks of aggregating the data, with top line results expected in mid-2027. Management said 95% of the sites are open, expanded NexoBrid facility work is expected to be completed in the fourth quarter of 2026, commercial supply remains expected in the second half of 2027, and there is some cushion in that 6-month period, but supply is not expected earlier. The company said its 2026 revenue outlook depends on ongoing U.S. government funding discussions, while a substantial portion of anticipated 2026 revenue is tied to the planned U.S.-based facility; the $24 million to $26 million guidance has a significant part tied to that facility. Management also described approximately $1 billion in U.S. peak sales across 3 chronic wound categories, a 50-patient DFU study, and an additional $3.3 million award bringing the room-temperature-stable NexoBrid program’s total budget to $21.8 million.

Mediwound Financial Statement Overview

Summary

Overall financial performance is weak: revenue has contracted materially (TTM ~$10.0M vs ~$17.0M in 2025 and ~$20.2M in 2024) and profitability is deeply negative (TTM net margin ~-235%) with sizable operating/free-cash burn (TTM OCF about -$26.4M; FCF about -$32.6M). The balance sheet is comparatively steadier with moderate leverage (debt-to-equity ~0.26), but equity has declined alongside ongoing losses.

Income Statement

18Very Negative

Balance Sheet

46Neutral

Cash Flow

21Negative
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue10.01M16.96M20.22M18.69M26.50M23.76M
Gross Profit1.95M3.25M2.63M3.58M13.16M8.77M
EBITDA-24.98M-21.47M-27.93M-4.80M-18.25M-11.38M
Net Income-23.51M-23.88M-30.22M-6.72M-19.60M-13.55M
Balance Sheet
Total Assets65.50M86.25M73.50M66.46M50.02M19.74M
Cash, Cash Equivalents and Short-Term Investments27.85M53.14M43.16M41.54M33.90M11.05M
Total Debt8.30M8.15M6.93M6.35M846.00K1.39M
Total Liabilities33.70M42.62M42.34M34.86M39.10M24.33M
Stockholders Equity31.79M43.63M31.15M31.59M10.91M-4.58M
Cash Flow
Free Cash Flow-32.56M-20.04M-19.90M-16.93M-12.44M-9.40M
Operating Cash Flow-26.41M-14.53M-13.62M-10.46M-11.88M-8.92M
Investing Cash Flow-989.69K-19.54M-8.40M-34.32M-481.00K3.55M
Financing Cash Flow-351.94K29.62M19.39M22.92M35.76M-1.05M

Mediwound Technical Analysis

Technical Analysis SentimentPositive
Last Price13.68

Price Trends

50DMA13.21Positive
100DMA13.59Positive
200DMA15.00Negative

Market Momentum

MACD0.16Positive
RSI53.79Neutral
STOCH42.24Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MDWD, the sentiment is Positive. The current price of 13.68 is above the 20-day moving average (MA) of 13.27, above the 50-day MA of 13.21, and below the 200-day MA of 15.00, indicating a neutral trend. The MACD of 0.16 indicates Positive momentum. The RSI at 53.79 is Neutral, neither overbought nor oversold. The STOCH value of 42.24 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for MDWD.

Mediwound Risk Analysis

Mediwound disclosed 58 risk factors in its most recent earnings report. Mediwound reported the most risks in the "Legal & Regulatory" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Legal & Regulatory - Litigation, compliance, new legislation, and taxation risks

Latest Risks Added

0 New Risks

Mediwound Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

MDWD against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
HUMAHUMA57Neutral$139.18M-1.10-591.73%―52.51%-82.58%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
VRCAVRCA46Neutral$53.94M-1.34-442.78%―-25.75%35.30%
MDWDMDWD46Neutral$176.61M-7.52-61.68%―-52.19%3.91%
ALDXALDX41Neutral$41.88M-2.17>-0.01%――56.04%
CRBPCRBP40Underperform$62.03M-0.47-100.96%――-10.49%
GALTGALT40Underperform$293.55M-8.4821.65%――42.26%

* Healthcare Sector Average

Performance Comparison

-50%0%50%100%MDWDGALTALDXCRBPVRCAHUMADec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
MDWD and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
MDWDMediwound13.68-4.18-23.40%
GALTGalectin Therapeutics (GALT)2.91-2.83-49.30%
ALDXAldeyra Therapeutics0.69-4.17-85.74%
CRBPCorbus Pharmaceuticals Holdings3.01-8.81-74.53%
VRCAVerrica Pharmaceuticals3.14-1.34-29.91%
HUMAHumacyte0.50-0.67-57.18%

Mediwound Corporate Events

MediWound Reports Third-Quarter 2026 Results and Corporate Update

Nov 12, 2026

On November 12, 2026, MediWound reported third-quarter revenue of $3.6 million, down from $5.4 million a year earlier, while gross profit rose to $1.0 million, or 28.5% of revenue, from $0.9 million, or 16.5%. Research and development expense increas...

MediWound Announces $17.25 Million Share Offering After Full Option Exercise

Nov 5, 2026

MediWound Ltd. is an Israeli biotechnology company focused on biological treatments for severe burns and chronic wounds, serving the specialized wound-care market. Its commercial and investigational products are intended to support non-surgical wound...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 14, 2026